Updated July 2026. This page tracks biologics and immunotherapies for atopic dermatitis — there is no true "atopic dermatitis vaccine" in clinical development. The field is dominated by cytokine-targeted monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and JAK inhibitors (upadacitinib, abrocitinib, ruxolitinib topical). Recent additions include Nemluvio (nemolizumab), an IL-31 receptor antagonist approved by the FDA August 2024 for moderate-to-severe AD and prurigo nodularis. OX40/OX40L blockade (rocatinlimab, amlitelimab) advanced through Phase 3 in 2025–2026 targeting durable disease remission after treatment cessation. Long-acting formulations, pediatric label expansions, and combination approaches with microbiome therapies are active research areas.

Comprehensive tracking of atopic dermatitis (AD/eczema) therapeutic development including biologics targeting Type 2 inflammation (IL-4, IL-13, IL-31, TSLP), JAK inhibitors, barrier-repairing therapies. Atopic dermatitis affects 31 million Americans (16.5 million adults, 15 million children), 223 million globally. Most common chronic inflammatory skin disease - severe pruritus (itching), eczematous lesions, skin barrier dysfunction, quality of life devastation. FDA-approved biologics: Dupixent (dupilumab, 2017), Adbry (tralokinumab, 2021), Ebglyss (lebrikizumab, 2024) - revolutionizing moderate-severe AD. JAK inhibitors: Rinvoq (upadacitinib oral, 2022), Cibinqo (abrocitinib oral, 2022), Opzelura (ruxolitinib topical, 2021). Novel approaches: OX40/OX40L blockade, anti-IL-33, microbiome therapies. Complementary to emollients and skincare routines.

⚠️ SEVERE QUALITY OF LIFE IMPACT:

Atopic dermatitis affects 31 million Americans (10% adults, 13% children - most common pediatric skin disease). Global burden 223 million. Hallmark symptom: severe pruritus (itching) - 80% rate as "unbearable," disrupts sleep 60-90% patients (averaging 2+ hours lost/night), impairs concentration, work/school performance. Psychological burden profound: Depression 30-40%, anxiety 40%, social isolation, suicidal ideation 15% severe AD (2x general population). Children: bullying, missed school days (13 days/year average severe AD), developmental delays. Adults: Job loss 21%, relationship difficulties 40%, sexual dysfunction. Financial burden: $5.3 billion annual US costs ($4.2B direct medical, $1.1B lost productivity). Out-of-pocket $800-2,000/year per patient. Biologics game-changing but expensive ($30-40K/year) with insurance barriers. Traditional treatments (topical steroids, calcineurin inhibitors) partially effective, side effects (skin thinning, burning), require multiple daily applications (poor adherence). Biologics targeting Type 2 inflammation offer disease modification - 75% improvement possible, sustained remission, quality of life restoration matching healthy controls.

🩺 Atopic Dermatitis Therapeutic Tracker Dashboard

AD Therapeutics by Development Phase